Who is sponsoring NCT03929588?

NCT03929588 is sponsored by EyeQue Corp..

What drugs are being tested in NCT03929588?

Interventions in NCT03929588: Hand-held device supported by a mobile application, Phoropter, Autorefractor.

What condition does NCT03929588 study?

NCT03929588 studies Refractive Errors, Astigmatism.

Is NCT03929588 still recruiting?

NCT03929588 is currently completed. Last updated 24 March 2022.

Are results published for NCT03929588?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-03-24 · How we verify

NCT03929588

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of a Hand-held Device Plus Mobile App Versus Standard Eye Care Devices in Measuring Refractive Error of the Eye

Completed NA Results posted Last updated 24 March 2022

What this trial tests

NA trial testing Hand-held device supported by a mobile application in Refractive Errors in 230 participants. Completed in 31 March 2020.

Timeline

7 May 2019

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	EyeQue Corp.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	double
Primary purpose	diagnostic
Enrollment	230
Start date	7 May 2019
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	1 location across United States

Drugs / interventions tested

Hand-held device supported by a mobile application
Phoropter
Autorefractor

Conditions studied

Refractive Errors — all drugs for Refractive Errors →
Astigmatism — all drugs for Astigmatism →

Sponsor

EyeQue Corp.

Who can join

Adults 30 to 65, any sex, with Refractive Errors or Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

BVCA Utilizing Refraction Results From Handheld Device Compared to Manual Refraction Methods for the Age Stratum 45 Through 65 Years Primary · Through study completion, an average of 5 months

Best-corrected visual acuity (BVCA) utilizing refraction results using the handheld device with supporting application will be compared to standard manual refraction methods (using a phoropter) for the age stratum 45 through 65 years.

BCVA handheld device

Group	Value	95% CI
All Participants	0.06	0.04 – 0.08

BCVA manual refraction

Group	Value	95% CI
All Participants	0.02	0 – 0.04

BCVA automated refraction

Group	Value	95% CI
All Participants	0.03	0.01 – 0.05

Sponsor's own description

Single-center, open-label, prospective study in healthy volunteers desiring refraction for correction of visual acuity to compare a handheld device supported by a mobile application with the phoropter and autorefractor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

End Points, Collection, Processing, and Time: Four Key Elements to Consider When Planning for Use of Handheld Devices in a Drug Development Setting.
Pradhan V, Heatherington AC, Bhattacharya I. · · 2020 · PMID 31944268 · DOI 10.1002/cpt.1740

Verify or expand the search:

Other recruiting trials for Refractive Errors

Currently open trials in the same condition.

NCT07460557 — Morphological Characteristics of the Maxillomandibular Region in a 3D Representation and the Refractive Status of the Ey · recruiting
NCT06913491 — Efficacy of PEEK Acuity Versus ETDRS Chart for Assessment of Visual Acuity and Refractive Error · active not recruiting
NCT07001124 — Comparative Efficacy of Duochrome Test Verse +1 Blur Test in Detecting Refracting Error Across Different Ages · NA · active not recruiting
NCT06668246 — Performance of Refractometers With Self-adjusting Lenses Compared to Cycloplegia in Children (REFRALENS) · active not recruiting
NCT05458323 — Cognitive Level Enhancement Through Vision Exams and Refraction · NA · recruiting

Other EyeQue Corp. trials

Trials by the same sponsor.

NCT04955379 — Study in Pediatric Volunteers of a Handheld Device Versus a Standard Diagnostic Device in Ophthalmic Refraction · NA · unknown
NCT04820218 — At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults · NA · completed
NCT04693247 — Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction · NA · unknown
NCT04693260 — A Clinical Study to Evaluate the Remote Monitoring of Myopia Patients With the EyeQue Insight · NA · completed
NCT04474041 — Study to Evaluate Visual Acuity Measured With the EyeQue Insight Versus a Standard Eyechart. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03929588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EyeQue Corp.
Last refreshed: 24 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing